$STTK· SEC filing ·

STTK Reports $0 Revenue, $0 EPS, Phase 1 SL-325 Data Q2 2026, Phase 2 Crohn's Q3 2026, $21.4M ATM Proceeds

Shattuck Labs, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $5.65

Post-detection moves

1h
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS